Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:28:42.111Z.
Calculation as of: 2026-10-06T21:28:42.111Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cae73e0f7d7453288b6b30bb28ae33caa2dcc4a3490ac3f0933bc7bc3ce0e433
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Palvella Therapeutics, Inc.
Market Cap
$1.84B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.83B
EV/EBITDA Ratio
13.48x
TTM Avg
17.09x
3Y Avg
17.06x
5Y Avg
16.05x
Market Cap
$1.83B
EV/EBITDA Ratio
N/A
TTM Avg
349.46x
3Y Avg
208.93x
5Y Avg
208.93x
Market Cap
$1.81B
EV/EBITDA Ratio
21.67x
TTM Avg
30.23x
3Y Avg
32.57x
5Y Avg
30.28x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.84B | N/A | N/A | N/A | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 13.48x | 17.09x | 17.06x | 16.05x |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | N/A | 349.46x | 208.93x | 208.93x |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.81B | 49.01x | 24.79x | 97.87x | 107.08x |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | 3.29x | 3.29x | 3.29x |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 21.67x | 30.23x | 32.57x | 30.28x |
| Xencor, Inc. (XNCR)vs › | $1.81B | N/A | 26.29x | 37.47x | 47.79x |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 170.26x | 162.32x | 213.45x | 213.45x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
